Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Receives $25.60 Consensus Target Price from Analysts

Shares of Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) have earned an average rating of “Buy” from the six brokerages that are presently covering the firm, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have covered the stock in the last year is $25.60.

A number of equities analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Actinium Pharmaceuticals in a report on Tuesday. Stephens assumed coverage on Actinium Pharmaceuticals in a report on Tuesday, May 14th. They issued an “overweight” rating and a $25.00 price objective for the company. StockNews.com raised Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, May 5th. Cantor Fitzgerald reissued an “overweight” rating and issued a $21.00 price objective on shares of Actinium Pharmaceuticals in a report on Tuesday, April 30th. Finally, Maxim Group increased their price objective on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, March 19th.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its position in shares of Actinium Pharmaceuticals by 6.0% in the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the biotechnology company’s stock valued at $11,325,000 after purchasing an additional 82,113 shares during the last quarter. Brandywine Global Investment Management LLC acquired a new stake in Actinium Pharmaceuticals during the third quarter worth about $1,033,000. Virtu Financial LLC grew its position in Actinium Pharmaceuticals by 319.2% during the first quarter. Virtu Financial LLC now owns 82,029 shares of the biotechnology company’s stock worth $642,000 after buying an additional 62,459 shares in the last quarter. Creative Financial Designs Inc. ADV grew its position in Actinium Pharmaceuticals by 19.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after buying an additional 3,175 shares in the last quarter. Finally, Sanders Morris Harris LLC acquired a new stake in Actinium Pharmaceuticals during the first quarter worth about $78,000. 27.50% of the stock is owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Stock Performance

NYSEAMERICAN:ATNM opened at $8.44 on Tuesday. Actinium Pharmaceuticals has a one year low of $4.00 and a one year high of $10.24. The stock has a market capitalization of $251.19 million, a P/E ratio of -4.93 and a beta of 0.08.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last announced its quarterly earnings data on Friday, April 26th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.11. As a group, equities research analysts predict that Actinium Pharmaceuticals will post -1.48 earnings per share for the current year.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.